Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Rad51 and Rad50 Genetic Polymorphisms From Homologous Recombination Repair Pathway Are Associated With Disease Outcomes and Organ Toxicities in Aml Publisher



Mohseni A1 ; Toogeh G2 ; Rostami S3 ; Faranoush M4 ; Sharifi MJ5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Thalassemia Research Center, Hemoglobinopthy Institute, Mazandaran University of Medical Sciences, Sari, Iran
  2. 2. Department of Internal Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Pediatric Growth and Development Research Center, Iran University of Medical Sciences, Tehran, Iran
  5. 5. Division of Laboratory Hematology and Blood Banking, Department of Medical Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, P.O. Box, Meshkin Fam Street, Shiraz, 71345-1744, Iran

Source: Blood Research Published:2024


Abstract

Background: Acute myeloid leukemia (AML) is a heterogeneous malignancy that responds to various therapies. The sensitivity of leukemia cells to chemotherapy is affected by the DNA damage response (DDR). In this study, we examined the association between RAD51 rs1801320, XRCC3 rs861539, NBS1 rs1805794, MRE11 rs569143, and RAD50 rs2299014 variants of the homologous recombination repair (HRR) pathway and AML outcomes. Material and methods: PCR–RFLP was applied for the genotyping of 67 newly diagnosed cases. We performed Sanger sequencing to confirm the results of RFLP genotyping. Outcomes and organ toxicities were collected and χ2 testing was performed for association analysis. Results: RAD50 variant allele carriers were protected from renal and hepatic toxicities (p = 0.024 and p = 0.045, respectively), and were associated with resistant disease (p = 0.001). RAD51 variant alleles were protected from liver toxicity (p = 0.031) and correlated with disease resistance (p = 0.012). Conclusion: RAD50 rs2299014 and RAD51 rs1801320 polymorphisms may be useful for drug adjustment in AML. © The Author(s) 2024.
Related Docs
1. Genetic Variants of Nucleotide Excision Repair Pathway and Outcomes of Induction Therapy in Acute Myeloid Leukemia, Personalized Medicine (2019)
2. Polymorphism in the Dna Repair Gene Xrcc3 and Therapeutic Outcomes in Patients With Aml, Genetics in the Third Millennium (2015)
3. Toll-Like Receptor 4 Signaling Pathway Is Correlated With Pathophysiological Characteristics of Aml Patients and Its Inhibition Using Tak-242 Suppresses Aml Cell Proliferation, International Immunopharmacology (2021)
4. Ultrasensitive Quantitation of Flt3-Itd Mutation in Patients With Acute Myeloid Leukemia Using Ddpcr, Molecular Biology Reports (2023)
5. Investigation of Cebpa and Cebpa-As Genes Expression in Acute Myeloid Leukemia, Reports of Biochemistry and Molecular Biology (2019)
6. High Expression of Long Noncoding Rna Norad Is Associated With Poor Clinical Outcomes in Non-M3 Acute Myeloid Leukemia Patients, Hematology/ Oncology and Stem Cell Therapy (2023)
7. Studying the Potential of Upregulated Ptgs2 and Vegf-C Besides Hyper-Methylation of Ptgs2 Promoter As Biomarkers of Acute Myeloid Leukemia, Molecular Biology Reports (2022)
8. Transplantation, Clinical Immunology (2022)
Experts (# of related papers)
View all Related Experts
Shahrbano Rostami (2)
Gholamreza Toogeh (1)